Skip to main content

Table 5 Safety and adverse events, number of events (%)

From: Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

  FEIBA
n = 6
Placebo
n = 6
Number of patients with AEs 2 0
30-day mortality 2 (33) 0
Cerebrovascular accident 2 (33) 0
Thromboembolism 0 0
Deep vein thrombosis/pulmonary embolism 0 0
Myocardial infarction 0 0
Renal replacement therapy 1 (17) 0
  1. FEIBA, factor eight inhibitor bypass activity; AEs, adverse events